Summary

US Apheresis Service Market Research Report Information by Service Type (Donor/Automated Apheresis, Therapeutic Apheresis, and Stem Cell Collection and Processing), by Application (Neurological Disorders, Autoimmune Disorders, Hematologic Disorders, Oncology, Metabolic Toxicology Disorders, Infectious Diseases, Cardiovascular Disorders, and Others), by End User (Hospitals, Blood Banks, Specialty Clinics, Research Laboratories, and Biotechnology Pharmaceutical Companies) Forecast to 2035
Market Overview
During the forecast period (2025-2035), the US Apheresis Service Market is expected to experience a substantial compound annual growth rate (CAGR) of 8.47%. Apheresis is a medical procedure that involves the extraction of blood from a patient or donor, the separation of a specific component (such as plasma, platelets, or white blood cells), and the subsequent return of the residual blood to the body. It is frequently employed for therapeutic purposes, such as the removal of superfluous components in specific diseases (e.g., excess white blood cells in leukemia) or the collection of specific blood products for transfusions, such as platelets or plasma.
The growth of the US Apheresis Market is being driven by the rising demand for plasma-derived therapies, the increasing prevalence of chronic diseases, and favorable reimbursement policies. Furthermore, the market is constrained by the recruitment of voluntary non-remunerated donors, safety concerns in blood transfusions, and high procedure costs. Nevertheless, the market will experience development opportunities in the future due to the growing demand for platelet-rich plasma therapy and apheresis for pediatric and leukemia patients.

Market Segmentation
The US Apheresis Service Market has been segmented into Donor/Automated Apheresis, Therapeutic Apheresis, and Stem Cell Collection and Processing, based on the type of service provided.
The US Apheresis Service Market has been segmented into the following applications: Neurological Disorders, Autoimmune Disorders, Hematologic Disorders, Oncology, Metabolic Toxicology Disorders, Infectious Diseases, Cardiovascular Disorders, and Others. The Oncology segment is the fastest growing segment during the forecast period, while the Hematologic Disorders segment held the largest market in 2024.
The US Apheresis Service Market has been segmented into the following based on the end user: Hospitals, Blood Banks, Specialty Clinics, Research Laboratories, and Biotechnology Pharmaceutical Companies.
The US Apheresis Service Market has been segmented into North, South, Midwest, and West based on region. It is anticipated that South will account for the largest market share in 2024 and will reach USD 757.67 million by 2035. During the forecast period, it is expected to grow at the maximum CAGR of 9.63%.

Major Players
Versiti, Fresenius Medical Care, Carter BloodCare, ImpactLife, Mayo Clinic, The New York Blood Center (NYBC), The American Red, BioBridge Global, and San Diego Blood Bank (SDBB) are the primary participants in the US Apheresis Service Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 13
2 MARKET INTRODUCTION 15
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 RESEARCH OBJECTIVE 15
2.4 MARKET STRUCTURE 16
3 RESEARCH METHODOLOGY 17
3.1 OVERVIEW 17
3.2 DATA FLOW 19
3.2.1 DATA MINING PROCESS 19
3.3 PURCHASED DATABASE: 20
3.4 SECONDARY SOURCES: 21
3.4.1 SECONDARY RESEARCH DATA FLOW: 22
3.5 PRIMARY RESEARCH: 23
3.5.1 PRIMARY RESEARCH DATA FLOW: 24
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 25
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 26
3.6.1 REVENUE ANALYSIS APPROACH 26
3.7 DATA FORECASTING 27
3.7.1 DATA FORECASTING TYPE 27
3.8 DATA MODELING 28
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 28
3.8.2 DATA MODELING: 29
3.9 TEAMS AND ANALYST CONTRIBUTION 31
4 MARKET DYNAMICS 33
4.1 INTRODUCTION 33
4.2 DRIVERS 34
4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES 34
4.2.2 RISING DEMAND FOR PLASMA-DERIVED THERAPIES 34
4.2.3 FAVORABLE REIMBURSEMENT POLICIES 35
4.3 RESTRAINTS 36
4.3.1 HIGH PROCEDURE COSTS 36
4.3.2 SAFETY CONCERNS IN BLOOD TRANSFUSIONS 36
4.3.3 RECRUITMENT OF VOLUNTARY NON-REMUNERATED DONORS 37
4.4 OPPORTUNITY 38
4.4.1 INCREASING DEMAND FOR PLATELET-RICH PLASMA THERAPY 38
4.4.2 APHERESIS FOR LEUKEMIA AND PEDIATRIC PATIENTS 39
5 MARKET FACTOR ANALYSIS 40
5.1 PORTER'S FIVE FORCES MODEL 40
5.1.1 THREAT OF NEW ENTRANTS 40
5.1.2 BARGAINING POWER OF SUPPLIERS 41
5.1.3 THREAT OF SUBSTITUTES 41
5.1.4 BARGAINING POWER OF BUYERS 41
5.1.5 INTENSITY OF RIVALRY 41
5.2 IMPACT OF COVID-19 ON THE US APHERESIS MARKET 41
6 US APHERESIS SERVICE MARKET, BY SERVICE TYPE 44
6.1 OVERVIEW 44
7 US APHERESIS SERVICE MARKET, BY APPLICATION 47
7.1 OVERVIEW 47
8 US APHERESIS SERVICE MARKET, BY END USER 50
8.1 OVERVIEW 50
9 US APHERESIS SERVICE MARKET, BY REGION 53
9.1 OVERVIEW 53
9.2 NORTH 55
9.3 SOUTH 57
9.4 MIDWEST 59
9.5 WEST 61
10 COMPETITIVE LANDSCAPE 64
10.1 INTRODUCTION 64
10.2 MARKET SHARE ANALYSIS, 2024 64
10.3 COMPETITOR DASHBOARD 65
10.4 PUBLIC PLAYERS STOCK SUMMARY 66
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL 66
10.1 KEY DEVELOPMENTS & GROWTH STRATEGIES 66
10.1.1 FACILITY LAUNCH 66
10.1.2 ACQUISITION 67
10.1.3 PARTNERSHIP 67
10.1.4 TRANSITION 67
11 COMPANY PROFILES 68
11.1 VERSITI 68
11.1.1 COMPANY OVERVIEW 68
11.1.2 FINANCIAL OVERVIEW 69
11.1.3 SERVICES OFFERED 69
11.1.4 KEY DEVELOPMENTS 69
11.1.5 SWOT ANALYSIS 70
11.1.6 KEY STRATEGIES 70
11.2 FRESENIUS MEDICAL CARE AG 71
11.2.1 COMPANY OVERVIEW 71
11.2.2 FINANCIAL OVERVIEW 72
11.2.3 SERVICES OFFERED 72
11.2.4 KEY DEVELOPMENTS 73
11.2.5 SWOT ANALYSIS 73
11.2.6 KEY STRATEGIES 73
11.3 VITALANT 74
11.3.1 COMPANY OVERVIEW 74
11.3.2 FINANCIAL OVERVIEW 75
11.3.3 SERVICES OFFERED 75
11.3.4 KEY DEVELOPMENTS 75
11.3.5 SWOT ANALYSIS 76
11.3.6 KEY STRATEGIES 76
11.4 CARTER BLOODCARE 77
11.4.1 COMPANY OVERVIEW 77
11.4.2 FINANCIAL OVERVIEW 77
11.4.3 SERVICES OFFERED 78
11.4.4 KEY DEVELOPMENTS 78
11.4.5 KEY STRATEGIES 78
11.5 IMPACTLIFE 79
11.5.1 COMPANY OVERVIEW 79
11.5.2 FINANCIAL OVERVIEW 79
11.5.3 SERVICES OFFERED 80
11.5.4 KEY DEVELOPMENTS 80
11.5.5 KEY STRATEGIES 80
11.6 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER) 81
11.6.1 COMPANY OVERVIEW 81
11.6.2 FINANCIAL OVERVIEW 81
11.6.3 SERVICES OFFERED 81
11.6.4 KEY DEVELOPMENTS 82
11.6.5 KEY STRATEGIES 82
11.7 NEW YORK BLOOD CENTER (NYBC) 83
11.7.1 COMPANY OVERVIEW 83
11.7.2 FINANCIAL OVERVIEW 83
11.7.3 SERVICES OFFERED 84
11.7.4 KEY DEVELOPMENTS 84
11.7.5 SWOT ANALYSIS 84
11.7.6 KEY STRATEGIES 84
11.8 THE AMERICAN NATIONAL RED CROSS 85
11.8.1 COMPANY OVERVIEW 85
11.8.2 FINANCIAL OVERVIEW 85
11.8.3 SERVICES OFFERED 86
11.8.4 KEY DEVELOPMENTS 86
11.8.5 SWOT ANALYSIS 86
11.8.6 KEY STRATEGIES 86
11.9 BIOBRIDGE GLOBAL 88
11.9.1 COMPANY OVERVIEW 88
11.9.2 FINANCIAL OVERVIEW 88
11.9.3 SERVICES OFFERED 89
11.9.4 KEY DEVELOPMENTS 89
11.9.5 KEY STRATEGIES 89
11.10 SAN DIEGO BLOOD BANK 90
11.10.1 COMPANY OVERVIEW 90
11.10.2 FINANCIAL OVERVIEW 90
11.10.3 SERVICES OFFERED 90
11.10.4 KEY DEVELOPMENTS 91
11.10.5 KEY STRATEGIES 91
12 DATA CITATIONS 92